RASGEF1B inhibitors are a class of chemical compounds specifically designed to target and inhibit the function of RASGEF1B, a guanine nucleotide exchange factor (GEF) that plays a crucial role in regulating small GTPases, particularly those in the Ras superfamily. As a GEF, RASGEF1B facilitates the activation of Ras-related GTPases by promoting the exchange of GDP for GTP, thereby converting these GTPases into their active state. Once activated, Ras proteins and other GTPases influence a variety of cellular processes, including cell proliferation, differentiation, migration, and intracellular trafficking. RASGEF1B is involved in modulating key signaling pathways that are dependent on the proper activation of Ras GTPases. Inhibitors of RASGEF1B act by preventing its ability to catalyze nucleotide exchange, which blocks the activation of downstream Ras GTPases and disrupts the signaling cascades regulated by these molecular switches.
The inhibition of RASGEF1B can lead to disruptions in critical signaling pathways that rely on Ras GTPase activation, affecting processes such as cell growth and cytoskeletal reorganization. By blocking the function of RASGEF1B, these inhibitors prevent the conversion of Ras-related GTPases from their inactive to active state, which can result in altered cell behavior, including changes in adhesion, migration, and intracellular signaling dynamics. Researchers use RASGEF1B inhibitors to study the specific role of this GEF in cellular signaling networks and to understand how the regulation of GTPase activity influences broader cellular processes. These inhibitors provide valuable insights into the mechanisms by which guanine nucleotide exchange factors modulate Ras signaling and other related pathways. Additionally, RASGEF1B inhibitors offer a deeper understanding of how GEFs contribute to the fine-tuning of intracellular communication and the regulation of cellular responses to environmental stimuli, enhancing our knowledge of how cells adapt and function in response to changing conditions.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Farnesyl thiosalicylic acid | 162520-00-5 | sc-205322 sc-205322A | 1 mg 5 mg | $61.00 $82.00 | 15 | |
A farnesylthiosalicylic acid derivative, Salirasib disrupts Ras membrane localization and function, potentially influencing RASGEF1B-mediated Ras activation indirectly by affecting the downstream Ras pathway. | ||||||
Tipifarnib | 192185-72-1 | sc-364637 | 10 mg | $720.00 | ||
An inhibitor of farnesyltransferase, Tipifarnib blocks the farnesylation of Ras proteins, potentially affecting RASGEF1B-mediated activation by inhibiting post-translational modification of Ras. | ||||||
Lonafarnib | 193275-84-2 | sc-482730 sc-482730A | 5 mg 10 mg | $173.00 $234.00 | ||
Similar to Tipifarnib, Lonafarnib inhibits farnesyltransferase, impacting Ras activity and potentially altering the functional effects of RASGEF1B. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
A kinase inhibitor that targets several receptors, including RAF kinases in the Ras/Raf/MEK/ERK pathway. Sorafenib might indirectly influence RASGEF1B activity by inhibiting downstream signaling of Ras. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
An inhibitor of MEK, part of the MAPK/ERK pathway downstream of Ras. Trametinib could indirectly affect RASGEF1B activity by blocking signaling downstream of Ras activation. | ||||||
Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
Another MEK inhibitor, Cobimetinib could have an indirect effect on RASGEF1B-mediated Ras activation by inhibiting downstream MAPK/ERK signaling. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
A multi-targeted receptor tyrosine kinase inhibitor that can indirectly affect Ras signaling. While not directly targeting RASGEF1B, Sunitinib might influence pathways involving Ras activation. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
An EGFR tyrosine kinase inhibitor. By inhibiting EGFR, Gefitinib could indirectly affect RASGEF1B-related signaling pathways, as EGFR activation can lead to Ras activation. | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $75.00 $121.00 | 33 | |
Similar to Gefitinib, Erlotinib inhibits EGFR, potentially impacting RASGEF1B-mediated pathways by reducing upstream signals that lead to Ras activation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Inhibits PI3K, impacting AKT signaling. While not directly linked to RASGEF1B, LY294002 could affect cellular processes and pathways that are influenced by Ras activation. | ||||||